VTYX - CIK 0001851194
The table below shows Ventyx Biosciences, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $17.71M | $22.27M | $22.90M | $30.63M | $27.80M | $33.75M |
| SG&A |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $7.17M |
| $7.07M |
| $7.20M |
| $7.92M |
| $7.91M |
| $8.02M |
| Operating income | -$24.87M | -$29.33M | -$30.10M | -$38.55M | -$35.71M | -$41.77M |
| Income tax | - | - | - | - | - | - |
| Net income | -$22.83M | -$26.99M | -$27.44M | -$35.25M | -$31.95M | -$38.57M |
| EPS (diluted) | -$0.32 | -$0.38 | -$0.39 | -$0.50 | -$0.50 | -$0.62 |